Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

Tourmaline Bio, Inc. (TRML)

Compare
12.83
-0.29
(-2.21%)
At close: April 4 at 4:00:00 PM EDT
12.21
-0.62
(-4.83%)
After hours: April 4 at 7:52:29 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Sandeep C. Kulkarni M.D. Co-Founder, CEO & Director 753.02k -- 1983
Dr. Kevin B. Johnson M.B.A., Ph.D. Chief Regulatory Officer 555.84k -- 1964
Mr. Ryan Robinson CPA CFO & Treasurer -- -- 1988
Dr. Susan Dana Jones Ph.D. Chief Technology Officer -- -- 1960
Mr. W. Bradford Middlekauff J.D. Chief Business Officer, General Counsel & Corporate Secretary -- -- 1962
Ms. Kimberly Piorkowski Vice President of People, Culture & Compliance -- -- --
Ms. Dora Rau Senior VP & Head of Quality -- -- --
Mr. Gerhard Hagn Pharm.D. Senior VP and Head of Commercial & Business Development -- -- --
Dr. Emil M. deGoma M.D. Senior Vice President of Medical Research -- -- --
Dr. Kristine Erickson O.D., Ph.D. VP & TA Head of Ophthalmology, Medical Research -- -- --

Tourmaline Bio, Inc.

27 West 24th Street
Suite 702
New York, NY 10010
United States
646 481 9832 https://www.tourmalinebio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
74

Description

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Corporate Governance

Tourmaline Bio, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 9. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC

Tourmaline Bio, Inc. Earnings Date

Recent Events

March 13, 2025 at 12:00 AM UTC

S-8: Offering Registrations

December 10, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 12, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

November 8, 2024 at 12:00 AM UTC

SC 13G: Tender Offer/Acquisition Reports

November 7, 2024 at 12:00 AM UTC

S-3: Offering Registrations

October 22, 2024 at 12:00 AM UTC

SC 13G: Tender Offer/Acquisition Reports

October 10, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 11, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 5, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers